Should You Invest In These 5%+ Yielders? Anglo American plc, GlaxoSmithKline plc, Telecom Plus PLC & Admiral Group plc

Royston Wild explains the investment appeal of Anglo American plc (LON: AAL), GlaxoSmithKline plc (LON: GSK), Telecom plus PLC (LON: TEP) and Admiral Group plc (LON: ADM).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at whether you should stash your cash in these four big-yield behemoths.

Anglo American

At first glance Anglo American (LSE: AAL) may be an attractive pick for those seeking brilliant investment returns. According to City forecasts the mining colossus is set to deliver a dividend of 85 US cents per share in both 2015 and 2016, matching the payouts seen in the past three periods. Consequently the business offers a market-beating yield of 5.4% through to the close of next year.

But I believe that these predictions may fall short of estimates, as severe supply/demand imbalances across its critical markets threaten a fourth successive earnings slide for this year and potentially beyond. With Anglo American also nursing a $12.9bn net debt pile as of the turn of 2015 — and prospective dividends covered just 1.2 times and 1.6 times for this year and next, well below the safety market of 2 times — I believe the metals play is a perilous pick for income seekers.

GlaxoSmithKline

Conversely, I believe that GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is a strong dividend pick for the near term and stretching further ahead. The pharma giant announced plans last month to fork out an ordinary dividend of 80p per share through to the close of 2017, forecasts that carry a chunky yield of 5.4%.

Like Anglo American, GlaxoSmithKline boasts poor dividend cover for the next few years, with projected earnings of 81.9p for 2015 and 89.5p for next year barely exceeding expected dividends. But the Brentford firm remains a brilliant cash generator despite the effect of expiring patents on profits, and is also undertaking massive restructuring to bolster the balance sheet and cut the debt column still further. And with GlaxoSmithKline’s revitalised R&D department ready to drive revenues higher again from this year, I expect dividends to continue outperforming the wider market.

Telecom Plus

Shares in Telecom Plus (LSE: TEP) have gradually stepped lower in recent months as gas and electricity prices have headed steadily lower. However, the business is expected keep the likes of Centrica, SSE et al on the back foot by continually improving its tariff range —  as illustrated by March’s new two-year tariff, part-funded by nPower — while Telecom Plus’ strategy of rewarding existing customers rather than courting new clients is also helping to maintain its consumer base.

As a consequence Telecom Plus is expected to see earnings tick comfortably higher through the next few years at least, driving a predicted dividend of 40p per share for the year concluding March 2015 to 46p in 2016 and to 52p the following year. Consequently the business boasts vast yields of 5.7% for this year and 6.4% for 2017.

Admiral Group

Although car insurance specialist Admiral (LSE: ADM) remains beset by intense competition, I believe that a gradual improvement in premiums should keep dividends bubbling along at above-average levels. This view is shared by the City, and the Swansea-based firm is expected to fork out rewards of 89.1p this year and 94.8p in 2016. As a result the insurer carries gigantic yields of 6% and 6.4% for these years.

While dividend coverage may be lacking over at Admiral — estimated payments are barely covered by earnings through to the end of next year — the firm is a terrific capital generator and saw cash and cash equivalents leap to £255.9m last year from £187.9m in 2013. With its operations on mainland Europe also pulling up trees, and Admiral boasting terrific customer retention rates, I believe the Cardiff firm should remain a lucrative payout pick.

 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Centrica. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

1 discounted US stock for me to buy for the cybersecurity revolution!

This AI-powered cybersecurity company's beating its rival technologies, and a recent share price drop may have just created a buying…

Read more »

Investing Articles

Buying 1,019 shares of this FTSE 100 monopoly could earn me £2,284 in passive income

National Grid’s monopoly status makes it a popular passive income stock. But investors shouldn’t underestimate the risks that come with…

Read more »

Investing Articles

£5k in savings? Here’s how I’d aim to build a rising passive income of £5,500 a month

Harvey Jones invests in FTSE 100 dividend stocks with the aim of generating a growing passive income to fund his…

Read more »

Investing Articles

Are these 2 legendary dividend stocks worth buying and holding until 2030?

Zaven Boyrazian explores two of the UK's most legendary dividend stocks with tremendous track records. But are they good long-term…

Read more »

Investing Articles

I’d listen to Warren Buffett’s advice and buy undervalued shares today

Warren Buffett’s focus on quality at a reasonable price has proven to be a highly lucrative strategy that other investors…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

How I’d aim to turn an empty ISA into a £50k second income!

Zaven Boyrazian outlines how investors can target a £50,000 second income starting with a brand new ISA while also keeping…

Read more »

Investing Articles

Up 202%! This hidden FTSE gem has outpaced the Rolls-Royce share price and is still climbing!

The Rolls-Royce share price may have outpaced every FTSE 100 rival over the last couple of years but Harvey Jones…

Read more »

Investing Articles

How I’d invest my first £1,000 in a SIPP

Investing the first £1,000 in an SIPP can be a daunting process, especially for new investors. Zaven Boyrazian explains what…

Read more »